Fri, Apr 19, 2024
A A A
Welcome Guest
Free Trial RSS pod
Get FREE trial access to our award winning publications
Industry Updates

ChinaAMC partners with TOBAM to develop unique Anti-Benchmark China A-shares investment capability

Wednesday, March 07, 2018
Opalesque Industry Update - TOBAM, Paris-based research driven quantitative asset manager and founder of the Maximum Diversification approach and China Asset Management Company (ChinaAMC), a Chinese asset manager, announce today a strategic partnership to develop a unique Anti-Benchmark China A-shares equity investment strategy.

The announcement that China's A Shares will be included in the MSCI Emerging Markets benchmarks by June 1st, 2018 has increased investors' needs for core strategies in Chinese equities.

The Anti-Benchmark China strategies will seek to maximize diversification across the CSI indexes (CSI 300, CSI 500 & CSI 800 universes) by applying TOBAM's patented Maximum Diversification approach, which is designed to avoid the risk biases that more traditional allocation methods such as market-cap weighting can lead to.

ChinaAMC will leverage their expertise and privileged access to the Chinese A-Shares equity markets and complement this with TOBAM's research capabilities and unique Anti-Benchmark® approach.

The strategy could prove a compelling solution for large, sophisticated institutional investors, well aware of the limitations of the market cap-weighted indices and actively looking for options to invest more efficiently. Also, the Anti-Benchmark CSI 300, CSI 500 and CSI 800 Equity strategies are potentially attractive for non-domestic investors who believe in the Chinese growth story but would like to access it in a diversified way that notably seeks to mitigate the risk concentrations that are to be found in the CSI indices.

Like in other markets, the implementation of the Maximum Diversification approach in the China A-Shares equity investment universe aims at delivering the risk premium of the asset class via diversification, which seeks to translate into both excess return and reduced volatility vs. the corresponding market cap-weighted index.

"Chinese clients have shown interest in various Smart Beta Strategies with pre-defined screening and weighting rules that overlay simple exposure to equity classes, and we expect these strategies to gain traction. Hence, we are keen to develop Smart Beta Strategies for the Chinese market based on appropriate risk measurements. The collaboration between ChinaAMC and TOBAM incorporates our research efforts to provide investors with a unique investment strategy." said Mr. Xiaodong Tang, CEO of ChinaAMC.

Yves Choueifaty, CEO of TOBAM says: "We are proud to partner with ChinaAMC to apply for the first time our Maximum Diversification® approach to Chinese A-shares equities. ChinaAMC's strong knowledge of the local market paired with TOBAM's research capabilities is a unique combination that we believe offers unprecedented investment opportunities in Chinese equities to investors worldwide."

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Previous Opalesque Exclusives                                  
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. KKR raises $6.4bn for the largest pan-Asia infrastructure fund[more]

    Laxman Pai, Opalesque Asia: The New York-based global investment firm KKR has raised a record $6.4bn for its second Asia-focused infrastructure fund, underlining investors' continued appetite for private markets. According to a media release from the alternative assets manager, the figure top

  2. Bucking the trend, top hedge fund makes plans for a second SPAC[more]

    From Institutional Investor: SPACs aren't dead. At least not to the folks at Cormorant Asset Management. The life sciences firm, whose hedge fund topped its peers in 2023, is confident it will match the success of its first blank-check company. Last week, the life sciences and biopharma speciali

  3. Benefit Street Partners closes fifth fund on $4.7 billion[more]

    Bailey McCann, Opalesque New York: Benefit Street Partners has closed its fifth flagship direct lending vehicle, BSP Debt Fund V, with $4.7 billion of investable capital across the strategy. Benefit Street invests primarily in privately originated, floating rate, senior secured loans. The fun

  4. 4 hedge fund themes that are working in 2024[more]

    From The Street: A poor earnings report from Tesla (TSLA) has not hurt the indexes on Thursday. The decline in Tesla stock, which is losing its position in the Magnificent Seven pantheon, is more than offset by strong earnings from IBM (IBM) and ServiceNow (NOW) . In addition, the much higher-t

  5. Opalesque Exclusive: A global macro fund eyes opportunities in bonds[more]

    Bailey McCann, Opalesque New York for New Managers: Munich-based ThirdYear Capital rebounded in 2023, following a tough year for global macro. The firm's flagship ART Global Macro strategy finished the year up 1